Onset of psoriasis with immune checkpoint inhibitor therapy: A systematic review

Nawar Tarafdar; Muskaan Sachdeva; Iryna Savinova; Yuliya Lytvyn; Khalad Maliyar; Jorge R Georgakopoulos; Asfandyar Mufti; Jensen Yeung

doi:10.1016/j.jaad.2023.09.070

Onset of psoriasis with immune checkpoint inhibitor therapy: A systematic review

J Am Acad Dermatol. 2024 Feb;90(2):392-395. doi: 10.1016/j.jaad.2023.09.070. Epub 2023 Oct 4.

Authors

Nawar Tarafdar¹, Muskaan Sachdeva², Iryna Savinova³, Yuliya Lytvyn², Khalad Maliyar², Jorge R Georgakopoulos², Asfandyar Mufti², Jensen Yeung⁴

Affiliations

¹ Western University, Schulich School of Medicine and Dentistry, London, Ontario, Canada.
² Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada.
³ Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Canada.
⁴ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada. Electronic address: jensen.yeung@utoronto.ca.

PMID: 37797837
DOI: 10.1016/j.jaad.2023.09.070

No abstract available

Keywords: atezolizumab; camrelizumab; cemiplimab; durvalumab; immune checkpoint inhibitor; immunotherapy; ipilimumab; nivolumab; pembrolizumab; psoriasis; systematic review.

Publication types

Systematic Review

MeSH terms

Humans
Immune Checkpoint Inhibitors* / adverse effects
Immune Checkpoint Inhibitors* / therapeutic use
Psoriasis* / drug therapy

Substances

Immune Checkpoint Inhibitors